CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues:
License and milestone fees	$ 18,730	$ 10,077
Non-cash royalty revenue related to the sale of future royalties	7,613	7,380
Research and development support	1,478	1,059
Clinical materials revenue	678	1,198
Total revenues	28,499	19,714
Operating Expenses:
Research and development	32,888	36,094
General and administrative	8,119	11,235
Restructuring charges	386
Total operating expenses	41,393	47,329
Loss from operations	(12,894)	(27,615)
Investment income, net	115	108
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes	(3,575)	(4,972)
Interest expense on convertible senior notes	(1,125)
Other income, net	134	551
Net loss	$ (17,345)	$ (31,928)
Basic and diluted net loss per common share (in dollar per share)	$ (0.20)	$ (0.37)
Basic and diluted weighted average common shares outstanding (in shares)	87,160	87,035
Total comprehensive loss	$ (17,345)	$ (31,928)